These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 10957771)

  • 21. Prostate-specific antigen: current status.
    Brawer MK
    CA Cancer J Clin; 1999; 49(5):264-81. PubMed ID: 11198954
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate-specific antigen and early detection of prostate cancer.
    Chu TM
    Tumour Biol; 1997; 18(2):123-34. PubMed ID: 9222310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Detection of prostate-specific antigen- or prostate-specific membrane antigen-positive circulating cells in prostatic cancer patients: clinical implications.
    Millon R; Jacqmin D; Muller D; Guillot J; Eber M; Abecassis J
    Eur Urol; 1999 Oct; 36(4):278-85. PubMed ID: 10473985
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
    Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The role of PSA in diagnosis of prostate cancer and its recurrence].
    Vergho DC; Heine K; Wolff JM
    Pathologe; 2005 Nov; 26(6):473-8. PubMed ID: 16215709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Additional aids in detection of prostate carcinomas? PSA-prostatic volume quotient, PSA-doubling time, age-dependent PSA reference values and PSA in urine].
    Pannek J; Brands FH
    Urologe A; 2000 Jul; 39(4):324-9. PubMed ID: 10957773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution!
    Eisenberger MA; Nelson WG
    J Natl Cancer Inst; 1996 Jun; 88(12):779-81. PubMed ID: 8637038
    [No Abstract]   [Full Text] [Related]  

  • 28. [Prostate cancer screening with a new marker based on circulating blood macrophages?].
    Herwig R; Djavan B; Kramer G; El-Taieb MA; Kühhas F; Leers M; Marberger M
    Urologe A; 2007 Sep; 46(9):1066-70. PubMed ID: 17622505
    [No Abstract]   [Full Text] [Related]  

  • 29. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer: do we know how to use it?
    Kuban DA; El-Mahdi AM; Schellhammer PF
    Semin Radiat Oncol; 1998 Apr; 8(2):72-80. PubMed ID: 9516587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
    Nadler RB; Loeb S; Roehl KA; Antenor JA; Eggener S; Catalona WJ
    J Urol; 2005 Dec; 174(6):2154-7, discussion 2157. PubMed ID: 16280754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: an empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection.
    Loeb S; Metter EJ; Carter HB
    J Natl Cancer Inst; 2011 Nov; 103(21):1636-7; author reply 1637. PubMed ID: 21926375
    [No Abstract]   [Full Text] [Related]  

  • 32. Incidental carcinoma of the prostate.
    van Andel G; Vleeming R; Kurth K; de Reijke TM
    Semin Surg Oncol; 1995; 11(1):36-45. PubMed ID: 7538693
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Duffy MJ
    Ann Clin Biochem; 2011 Jul; 48(Pt 4):310-6. PubMed ID: 21525152
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Prostate-specific antigen as a tumor marker of prostate carcinoma].
    Wymenga LF; Mensink HJ
    Ned Tijdschr Geneeskd; 1999 Aug; 143(34):1733-8. PubMed ID: 10494319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Management of patients with increasing PSA values after curative therapy].
    Fichtner J; Miller K
    Urologe A; 2000 Sep; 39(5):475-82. PubMed ID: 11045051
    [No Abstract]   [Full Text] [Related]  

  • 36. [PSA and hK2 in the diagnosis of prostate cancer].
    Alapont Alacreu JM; Navarro Rosales S; Budía Alba A; España Furió F; Morera Martínez F; Jiménez Cruz JF
    Actas Urol Esp; 2008 Jun; 32(6):575-88. PubMed ID: 18655340
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical value of total and free prostatic specific antigen in prostatic cancer].
    Liubimova NV; Kushlinskiĭ NE; Stogova EV; Bronnikov IIu; Gorilovskiĭ LM
    Klin Lab Diagn; 1998 Feb; (2):6-9. PubMed ID: 9553336
    [No Abstract]   [Full Text] [Related]  

  • 38. Usefulness of prostate-specific antigen density as a diagnostic test of prostate cancer.
    Filella X; Alcover J; Molina R; Carrere W; Carretero P; Ballesta AM
    Tumour Biol; 1996; 17(1):20-6. PubMed ID: 7501969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate-specific antigen and other serum markers: current concepts from the World Health Organization Second International Consultation on Prostate Cancer.
    Brawer MK; Benson MC; Bostwick DG; Djavan B; Lilja H; Semjonow A; Su S; Zhou Z
    Semin Urol Oncol; 1999 Nov; 17(4):206-21. PubMed ID: 10632122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predicted prostate specific antigen results using transrectal ultrasound gland volume. Differentiation of benign prostatic hyperplasia and prostate cancer.
    Lee F; Littrup PJ; Loft-Christensen L; Kelly BS; McHugh TA; Siders DB; Mitchell AE; Newby JE
    Cancer; 1992 Jul; 70(1 Suppl):211-20. PubMed ID: 1376190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.